Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


X0202 SCHEDULE 13D/A 0002038820 XXXXXXXX LIVE 4 Class A Common Stock, par value $0.001 per share 09/27/2026 false 0001802255 40145W101 Guardian Pharmacy Services, Inc. 300 Galleria Parkway SE Suite 800 Atlanta GA 30339 Bindley Capital Partners I LLC (317) 704-4162 (Attn: William E. Bindley) 8909 Purdue Road, Suite 500 Indianapolis IN 46268 0002038820 N Bindley Capital Partners I, LLC a OO N IN 16669666 0 16669666 0 16669666 N 26.3 OO The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock, par value $0.001 per share ("Class A common stock") outstanding as of September 27, 2026, of Guardian Pharmacy Services, Inc. (the "Issuer") as disclosed in the Issuer's Current Report on Form 8-K filed with the SEC on September 10, 2026 (the "8-K"). 0000903539 N William E. Bindley a OO N X1 0 16669666 0 16669666 16669666 N 26.3 IN William E. Bindley shares voting and investment power with Thomas J. Salentine, Jr. over an aggregate of 16,669,666 shares of Class A common stock currently owned by Bindley Capital Partners I, LLC ("Bindley Capital") by virtue of his position as member and officer of Bindley Capital Partners, LLC, the manager of Bindley Capital. The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K. 0002037899 N Thomas J. Salentine, Jr. a OO PF N X1 35714 16669666 35714 16669666 16705380 N 26.4 IN Thomas J. Salentine, Jr. directly owns 35,714 shares of Class A common stock. Mr. Salentine, Jr. also shares voting and investment power with William E. Bindley over an aggregate of 16,669,666 shares of Class A common stock currently owned by Bindley Capital by virtue of his position as member and officer of Bindley Capital Partners, LLC, the manager of Bindley Capital. The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K. 0002038519 N Pharmacy Investors, LLC a OO N IN 3863806 0 3863806 0 3863806 N 6.1 OO The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K. 0002037898 N John Ackerman a OO N X1 3863806 0 3863806 0 3863806 N 6.1 IN John Ackerman has voting and investment power over an aggregate of 3,863,806 shares of Class A common stock currently owned by Pharmacy Investors, LLC ("Pharmacy Investors") by virtue of his position as Manager of Pharmacy Investors. The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K. 0001432819 N Cardinal Equity Fund, L.P. a OO N DE 1287237 0 1287237 0 1287237 N 2.0 PN Investment and voting decisions for the shares held by Cardinal Equity Fund, L.P. ("Cardinal") require unanimous consent of the investment committee of Cardinal Equity Partners, LLC, the general partner of Cardinal. The investment committee consists of John Ackerman, James L. Smeltzer, Peter J. Munson and Michael E. Smith. Therefore, no individual member of the investment committee is deemed to be the beneficial owner of the shares reported in this Schedule 13D. The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K. 0002037972 N Fred P. Burke a OO N X1 3438064 0 3438064 0 3438064 N 5.4 IN The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K. 0002037977 N David K. Morris a OO N X1 877004 0 877004 0 877004 N 1.4 IN The shares reported in Rows 7, 9 and 11 in the table above exclude 641,870 shares of Class A common stock that Mr. Morris has agreed to transfer on or before November 11, 2026 pursuant a September 2025 domestic relations order, as previously disclosed. The percentage reflected in Row 13 in the table above is calculated based on 63,320,300 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K. 0002038507 N G. Kendall Forbes a OO N X1 1651059 0 1651059 0 1651059 N 2.6 IN The percentage reflected in Row 13 in the table above is calculated based on 63,320,304 shares of Class A common stock outstanding as of September 27, 2026 as disclosed in the 8-K. Class A Common Stock, par value $0.001 per share Guardian Pharmacy Services, Inc. 300 Galleria Parkway SE Suite 800 Atlanta GA 30339 EXPLANATORY NOTE: This Schedule 13D serves as Amendment No. 4 ("Amendment No. 4") to the Statement on Schedule 13D initially filed by the Reporting Persons (as defined below) on February 3, 2025, as amended by Amendment No. 1 thereto filed on May 29, 2025, Amendment No. 2 thereto filed on July 29, 2025, and Amendment No. 3 thereto filed on March 24, 2026 (and as further amended by this Amendment No. 4, the "Schedule 13D"). Except as specifically provided herein, this Amendment No. 4 does not modify any information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 4 shall have the same meanings herein as are ascribed to such terms in the Schedule 13D. This Amendment No. 4 is being jointly filed by Bindley Capital Partners I, LLC ("Bindley Capital"), William E. Bindley, Thomas J. Salentine, Jr., Pharmacy Investors, LLC ("Pharmacy Investors"), John Ackerman, Cardinal Equity Fund, L.P. ("Cardinal"), Fred P. Burke, David K. Morris and G. Kendall Forbes (each a "Reporting Person," and collectively, the "Reporting Persons"). As of the date hereof, the Reporting Persons, collectively, beneficially own 27,822,550 shares of Class A common stock. As of the date hereof, the Reporting Persons, collectively, beneficially own 27,822,550 shares of Class A common stock, representing approximately 43.9% of the shares of Class A common stock, calculated based on 63,320,300 shares of Class A common stock outstanding as disclosed in the 8-K. Of the 63,320,300 shares of Class A common stock currently outstanding, 13,521,396 shares of Class A common stock were issued upon the automatic conversion of an equal number of shares of the Issuer's Class B common stock, par value $0.001 per share, on September 27, 2026, pursuant to the Issuer's Amended and Restated Certificate of Incorporation. The aggregate number and percentage of shares of Class A common stock beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares of Class A common stock as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on Rows 7 through 11 and Row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference. Except as set forth in the Schedule 13D, no transactions in the shares of Class A common stock were effected by the Reporting Persons, or, to the knowledge of the Reporting Persons, any of the persons listed on Schedule A hereto in the 60 days preceding the date of the Schedule 13D. Except as described herein, to the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of Class A common stock of the Issuer beneficially owned by the Reporting Persons as described in this Item 5. Not applicable. Exhibit 99.1 Stockholders' Agreement, dated as of September 25, 2024, by and among Guardian Pharmacy Services, Inc., Bindley Capital Partners I, LLC, Pharmacy Investors, LLC, Cardinal Equity Fund LP, Fred Burke, David Morris and Kendall Forbes (incorporated by reference to Exhibit 4.1 of the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 30, 2024). Exhibit 99.2 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Exchange Act (incorporated by reference to the Schedule 13D filed with the Securities and Exchange Commission on February 3, 2025). Bindley Capital Partners I, LLC /s/ Thomas J. Salentine, Jr. Member 09/28/2026 William E. Bindley /s/ William E. Bindley, individually William E. Bindley, individually 09/28/2026 Thomas J. Salentine, Jr. /s/ Thomas J. Salentine, Jr., individually Thomas J. Salentine, Jr., individually 09/28/2026 Pharmacy Investors, LLC /s/ John Ackerman Managing Member 09/28/2026 John Ackerman /s/ John Ackerman, individually John Ackerman, individually 09/28/2026 Cardinal Equity Fund, L.P. /s/ John Ackerman, by Cardinal Equity Partners, LLC, its General Partner Managing Member 09/28/2026 Fred P. Burke /s/ Fred P. Burke, individually Fred P. Burke, individually 09/28/2026 David K. Morris /s/ David K. Morris, individually David K. Morris, individually 09/28/2026 G. Kendall Forbes /s/ G. Kendall Forbes, individually G. Kendall Forbes, individually 09/28/2026